Stacey Bagby
Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Xenograft Model Antitumor Assays | 25 | 2026 | 934 | 1.190 |
Why?
| | Colorectal Neoplasms | 13 | 2025 | 866 | 1.080 |
Why?
| | Melanoma | 9 | 2024 | 759 | 0.830 |
Why?
| | Antineoplastic Agents | 13 | 2020 | 2214 | 0.720 |
Why?
| | Adrenocortical Carcinoma | 4 | 2026 | 72 | 0.630 |
Why?
| | Protein Kinase Inhibitors | 8 | 2026 | 981 | 0.620 |
Why?
| | Mice, Nude | 16 | 2024 | 679 | 0.570 |
Why?
| | Carcinoma, Pancreatic Ductal | 4 | 2024 | 293 | 0.520 |
Why?
| | Proto-Oncogene Proteins B-raf | 4 | 2021 | 223 | 0.500 |
Why?
| | Cell Line, Tumor | 23 | 2026 | 3542 | 0.500 |
Why?
| | Adrenal Cortex Neoplasms | 3 | 2026 | 70 | 0.490 |
Why?
| | Drug Discovery | 1 | 2016 | 153 | 0.450 |
Why?
| | Azepines | 4 | 2024 | 105 | 0.440 |
Why?
| | Heterografts | 4 | 2021 | 143 | 0.430 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2024 | 218 | 0.420 |
Why?
| | Pyrimidines | 4 | 2020 | 530 | 0.410 |
Why?
| | Piperazines | 4 | 2021 | 375 | 0.410 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 734 | 0.410 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1963 | 0.400 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2024 | 1443 | 0.380 |
Why?
| | Pancreatic Neoplasms | 4 | 2024 | 928 | 0.380 |
Why?
| | Mice | 29 | 2026 | 18329 | 0.350 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2024 | 881 | 0.350 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2018 | 212 | 0.340 |
Why?
| | Cell Proliferation | 13 | 2026 | 2507 | 0.340 |
Why?
| | Quinoxalines | 3 | 2020 | 65 | 0.340 |
Why?
| | Histone Deacetylase Inhibitors | 2 | 2024 | 218 | 0.340 |
Why?
| | Dasatinib | 2 | 2024 | 58 | 0.330 |
Why?
| | Apoptosis | 14 | 2026 | 2440 | 0.300 |
Why?
| | Disease Models, Animal | 7 | 2022 | 4560 | 0.290 |
Why?
| | Animals | 32 | 2026 | 38030 | 0.270 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2025 | 992 | 0.270 |
Why?
| | Neoplasms | 5 | 2022 | 2906 | 0.270 |
Why?
| | Pyridines | 4 | 2022 | 609 | 0.240 |
Why?
| | Anilides | 2 | 2018 | 84 | 0.240 |
Why?
| | Deoxycytidine | 3 | 2024 | 220 | 0.240 |
Why?
| | Signal Transduction | 10 | 2024 | 5216 | 0.230 |
Why?
| | CD47 Antigen | 1 | 2025 | 42 | 0.230 |
Why?
| | Gene Regulatory Networks | 2 | 2024 | 317 | 0.210 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 624 | 0.200 |
Why?
| | Endogenous Retroviruses | 1 | 2024 | 37 | 0.200 |
Why?
| | Bevacizumab | 1 | 2024 | 168 | 0.200 |
Why?
| | Mucous Membrane | 1 | 2024 | 128 | 0.200 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2020 | 39 | 0.200 |
Why?
| | Benzimidazoles | 1 | 2024 | 189 | 0.190 |
Why?
| | Camptothecin | 3 | 2022 | 138 | 0.190 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 153 | 0.180 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 166 | 0.180 |
Why?
| | Immunotherapy | 3 | 2022 | 666 | 0.180 |
Why?
| | Wnt Signaling Pathway | 2 | 2024 | 211 | 0.170 |
Why?
| | Fluorouracil | 1 | 2022 | 231 | 0.170 |
Why?
| | beta Catenin | 2 | 2020 | 254 | 0.170 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2021 | 70 | 0.170 |
Why?
| | Humans | 41 | 2026 | 145475 | 0.170 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2021 | 53 | 0.170 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2021 | 49 | 0.170 |
Why?
| | Transplantation, Heterologous | 2 | 2022 | 170 | 0.160 |
Why?
| | Momordica charantia | 1 | 2020 | 12 | 0.160 |
Why?
| | Aurora Kinase A | 2 | 2020 | 61 | 0.160 |
Why?
| | Benzoxazoles | 1 | 2020 | 20 | 0.160 |
Why?
| | Neoplasms, Experimental | 2 | 2019 | 167 | 0.150 |
Why?
| | Immune System | 1 | 2021 | 180 | 0.150 |
Why?
| | eIF-2 Kinase | 1 | 2019 | 28 | 0.150 |
Why?
| | Adenine | 2 | 2020 | 339 | 0.150 |
Why?
| | Biomarkers, Tumor | 5 | 2021 | 1321 | 0.150 |
Why?
| | Pyrimidinones | 2 | 2021 | 125 | 0.150 |
Why?
| | Aniline Compounds | 1 | 2020 | 120 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 126 | 0.150 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 886 | 0.140 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2018 | 39 | 0.140 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 27 | 0.140 |
Why?
| | Plant Extracts | 1 | 2020 | 188 | 0.140 |
Why?
| | Pyridones | 2 | 2021 | 209 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 67 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.130 |
Why?
| | Adrenal Cortex | 1 | 2018 | 33 | 0.130 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.130 |
Why?
| | Drug Synergism | 2 | 2018 | 354 | 0.130 |
Why?
| | Female | 25 | 2026 | 78845 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 265 | 0.130 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 41 | 0.130 |
Why?
| | Armadillo Domain Proteins | 1 | 2017 | 6 | 0.130 |
Why?
| | src-Family Kinases | 1 | 2017 | 92 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2024 | 849 | 0.120 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2016 | 20 | 0.120 |
Why?
| | Neoplasm Metastasis | 2 | 2016 | 688 | 0.120 |
Why?
| | Cyclopentanes | 1 | 2016 | 17 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2017 | 41 | 0.120 |
Why?
| | Corynebacterium | 1 | 2017 | 49 | 0.120 |
Why?
| | Corynebacterium Infections | 1 | 2017 | 42 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 337 | 0.120 |
Why?
| | Tankyrases | 1 | 2016 | 13 | 0.120 |
Why?
| | Sulfonamides | 1 | 2020 | 583 | 0.120 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 3 | 2022 | 44 | 0.120 |
Why?
| | Autophagy | 1 | 2018 | 291 | 0.120 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2015 | 70 | 0.110 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2018 | 454 | 0.110 |
Why?
| | Mice, Inbred BALB C | 3 | 2025 | 1261 | 0.110 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2016 | 99 | 0.110 |
Why?
| | Receptor, Notch1 | 1 | 2015 | 63 | 0.110 |
Why?
| | Gene Dosage | 1 | 2015 | 145 | 0.110 |
Why?
| | Gene Expression Regulation | 1 | 2024 | 2597 | 0.110 |
Why?
| | Phosphorylation | 4 | 2019 | 1707 | 0.110 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2026 | 534 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 184 | 0.110 |
Why?
| | Pyrazoles | 1 | 2018 | 517 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 86 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2014 | 76 | 0.100 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 630 | 0.100 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 431 | 0.100 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2014 | 288 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 820 | 0.090 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 506 | 0.090 |
Why?
| | Cetuximab | 2 | 2025 | 111 | 0.080 |
Why?
| | Gene Expression Profiling | 3 | 2024 | 1767 | 0.080 |
Why?
| | Cell Survival | 3 | 2019 | 1100 | 0.080 |
Why?
| | Mutation | 2 | 2018 | 4075 | 0.080 |
Why?
| | Cell Cycle | 3 | 2018 | 598 | 0.080 |
Why?
| | Carcinogenesis | 2 | 2024 | 228 | 0.080 |
Why?
| | Mice, Inbred NOD | 2 | 2022 | 613 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2018 | 382 | 0.080 |
Why?
| | RNA, Small Interfering | 2 | 2024 | 637 | 0.070 |
Why?
| | Aged | 7 | 2025 | 26153 | 0.070 |
Why?
| | Middle Aged | 8 | 2025 | 36215 | 0.070 |
Why?
| | HCT116 Cells | 2 | 2018 | 76 | 0.060 |
Why?
| | Microsatellite Instability | 1 | 2025 | 55 | 0.060 |
Why?
| | Tumor Burden | 2 | 2018 | 325 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 2 | 2018 | 238 | 0.050 |
Why?
| | Neovascularization, Pathologic | 2 | 2018 | 286 | 0.050 |
Why?
| | Immunoblotting | 2 | 2015 | 295 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2018 | 440 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2024 | 157 | 0.050 |
Why?
| | DNA Damage | 1 | 2026 | 437 | 0.050 |
Why?
| | Adult | 6 | 2025 | 40777 | 0.050 |
Why?
| | Male | 8 | 2025 | 72843 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 1 | 2024 | 191 | 0.050 |
Why?
| | Paclitaxel | 1 | 2024 | 257 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 187 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 1 | 2025 | 666 | 0.050 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 69 | 0.050 |
Why?
| | Histone Deacetylase 1 | 1 | 2022 | 23 | 0.040 |
Why?
| | Inflammasomes | 1 | 2023 | 144 | 0.040 |
Why?
| | Organoids | 1 | 2024 | 145 | 0.040 |
Why?
| | Doxorubicin | 1 | 2024 | 401 | 0.040 |
Why?
| | Quinolines | 1 | 2022 | 190 | 0.040 |
Why?
| | Acetylation | 1 | 2022 | 259 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 439 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 35 | 0.040 |
Why?
| | Immune Tolerance | 1 | 2023 | 385 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 77 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 78 | 0.040 |
Why?
| | Aminopyridines | 1 | 2021 | 129 | 0.040 |
Why?
| | Membrane Proteins | 2 | 2018 | 1164 | 0.040 |
Why?
| | Histone Deacetylases | 1 | 2022 | 207 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 369 | 0.040 |
Why?
| | Pyrroles | 1 | 2021 | 220 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2020 | 106 | 0.040 |
Why?
| | Indolizines | 1 | 2019 | 13 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2020 | 210 | 0.040 |
Why?
| | Forkhead Box Protein M1 | 1 | 2019 | 11 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 138 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 97 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 825 | 0.040 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2018 | 23 | 0.040 |
Why?
| | Azetidines | 1 | 2018 | 45 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 4316 | 0.040 |
Why?
| | GTP Phosphohydrolases | 1 | 2018 | 93 | 0.030 |
Why?
| | 4-Aminobenzoic Acid | 1 | 2018 | 8 | 0.030 |
Why?
| | HT29 Cells | 1 | 2018 | 37 | 0.030 |
Why?
| | Aldosterone | 1 | 2018 | 42 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1454 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1044 | 0.030 |
Why?
| | RNA | 1 | 2024 | 910 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 198 | 0.030 |
Why?
| | Piperidines | 1 | 2018 | 222 | 0.030 |
Why?
| | Protein Transport | 1 | 2018 | 442 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 176 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2018 | 343 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2016 | 90 | 0.030 |
Why?
| | Axin Protein | 1 | 2016 | 18 | 0.030 |
Why?
| | Histones | 1 | 2022 | 666 | 0.030 |
Why?
| | Ubiquitination | 1 | 2016 | 118 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 105 | 0.030 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2016 | 23 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 397 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2016 | 49 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 442 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2016 | 246 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1845 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2017 | 155 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2016 | 194 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 22 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 66 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 254 | 0.030 |
Why?
| | Diphenylamine | 1 | 2014 | 7 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 699 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2016 | 267 | 0.030 |
Why?
| | Neoplastic Stem Cells | 1 | 2018 | 409 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 108 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 221 | 0.030 |
Why?
| | RNA Interference | 1 | 2016 | 475 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 3124 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 376 | 0.020 |
Why?
| | Benzamides | 1 | 2014 | 226 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 749 | 0.020 |
Why?
| | Transfection | 1 | 2016 | 926 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 530 | 0.020 |
Why?
| | Up-Regulation | 1 | 2016 | 847 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3155 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2023 | 5983 | 0.020 |
Why?
| | Protein Binding | 1 | 2018 | 2238 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1716 | 0.020 |
Why?
| | Models, Biological | 1 | 2018 | 1764 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11772 | 0.020 |
Why?
| | Transcriptome | 1 | 2015 | 1038 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2015 | 1505 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3904 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8333 | 0.010 |
Why?
|
|
Bagby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|